Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51

被引：39

作者：

Dubischar-Kastner, Katrin ^{[1
]}

Eder, Susanne ^{[1
]}

Buerger, Vera ^{[1
]}

Gartner-Woelfl, Gabriele ^{[1
]}

Kaltenboeck, Astrid ^{[1
]}

Schuller, Elisabeth ^{[1
]}

Tauber, Erich ^{[1
]}

Klade, Christoph ^{[1
]}

机构：

[1] Intercell AG, A-1030 Vienna, Austria

来源：

VACCINE | 2010年 / 28卷 / 32期

关键词：

Japanese encephalitis virus; Vaccine; Booster; TICK-BORNE ENCEPHALITIS; VIRUS-VACCINE; CONTROLLED PHASE-3; IMMUNOGENICITY; IMMUNIZATION; SAFETY; TRIAL; BLIND;

D O I：

10.1016/j.vaccine.2010.05.069

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IC51 (IXIARO (R), JESPECT (R)) is a recently approved prophylactic Japanese encephalitis virus vaccine with a two-vaccine primary immunization regimen. In this phase 3 trial, after primary immunization with a Day 0/28 dose schedule, seroprotection rates were 83%, 58% and 48% at Month 6, Month 12 and Month 24, respectively. A booster dose at Month 11 and/or Month 23 in subjects with neutralizing antibody titers below the limit of detection (defined as a serum dilution giving a 50% reduction of plaque counts in a plaque reduction neutralization test [PRNT50] <1:10) led to 100% seroconversion. After a single-dose immunization (incomplete primary immunization), only 9% of subjects were seroprotected at Month 6: however, a booster dose at Month 11 led to seroconversion in 99% of subjects. Hence, subjects with incomplete primary immunization can complete their schedule within at least 11 months. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5197 / 5202

页数：6

共 16 条

[1]

Altman DG, 2000, Statistics with confidence, V2nd

[2] Japanese Encephalitis in Travelers: Review of Cases and Seasonal Risk [J].